Noven To Report 2007 Fourth Quarter And Full Year Financial Results And Host Conference Call On March 27, 2008

SEC Comment Resolved, Noven to Maintain Current Revenue Recognition Policy

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that it will release its 2007 fourth quarter and full year financial results before the market opens on Thursday, March 27, 2008. Noven management will host a conference call that same morning at 8:30 a.m. ET to review the financial results and answer questions.

Noven also indicated that it will maintain its current revenue recognition accounting policy following resolution of a previously announced comment from the Securities and Exchange Commission (“SEC”). As announced on March 12, 2008, the company delayed the release of its 2007 financial results and the filing of its 2007 Form 10-K due to an open comment relating to revenue recognition raised in an SEC comment letter. Noven has confirmed that the SEC has completed its review and analysis and has no objection to Noven’s current revenue recognition policy. Accordingly, Noven will maintain its current policy, and no restatement of prior financial periods will be required as a result of the SEC comment. With this matter resolved, Noven expects to file its 2007 Annual Report on Form 10-K with the SEC within the previously announced extended filing period, which ends April 1, 2008.

The conference call with management will be broadcast live on March 27 at 8:30 a.m. ET at www.noven.com, and thereafter a rebroadcast will be accessible at the same site for at least two weeks. A taped replay of the call will be available beginning March 27 through March 29 by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering account number 286 and conference ID number 279741.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s leading transdermal products utilize its proprietary DOT Matrix® drug delivery technology and include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD. Oral products currently offered through Noven’s psychiatry/CNS marketing and sales organization consist of Pexeva® (paroxetine mesylate) and Lithobid® (lithium carbonate). Developmental products include Stavzor™ (delayed release valproic acid capsule) and Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product for vasomotor symptoms. See www.noven.com for additional information.

Safe Harbor Statement under the Private Litigation Reform Act of 1995
Except for historical information contained herein, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve substantial risks and uncertainties. Statements that are not historical facts, including statements that are preceded by, followed by, or that include, the words "believes," "anticipates," "plans," "expects" or similar expressions and statements are forward-looking statements. Noven’s estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect Noven’s current perspective on existing trends and information. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the current expectations of Noven and are subject to a number of risks and uncertainties that are subject to change based on factors that are, in many instances, beyond Noven's control.

These risks and uncertainties include the risk that unanticipated events could change Noven’s expectations regarding the timing of the filing of its 2007 Annual Report on Form 10-K, the resolution of the revenue recognition accounting policy comment, and/or Noven’s revenue recognition accounting policy. For additional information regarding these and other risks associated with Noven’s business, readers should refer to Noven’s Annual Report on Form 10-K as well as other reports filed from time to time with the Securities and Exchange Commission. Unless required by law, Noven undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
305-253-1916